Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Geriatrics Reports
Published in: Current Geriatrics Reports 2/2012

01-06-2012 | Biomarkers in the Classification of Biological Health and Disease Aging (Y Shen, Section Editor)

The Analytical Aspects and Regulatory Challenges of Biomarker Discovery: Examples from the Field of Neurodegeneration

Authors: Robert L. Martone, Richard Snyder, Arron S. L. Xu, Rachel Y. Reams

Published in: Current Geriatrics Reports | Issue 2/2012

Login to get access

Abstract

Drug discovery is guided by theories regarding disease pathogenesis, and biomarkers are the essential analytical tools used to translate those theories into clinical experiments. Biomarkers can be used to expedite clinical trials by permitting selection of the most uniform and responsive patient population, by reporting on target engagement of a particular therapeutic mechanism, and by permitting measurement of biochemical or physiological correlates of disease mechanism with end points that may be more sensitive, immediate, or statistically robust than phenotypic or behavioral changes. Biomarker discovery necessarily begins with an analytically validated assay for an analyte, which is later qualified by demonstrating its utility in some context of disease and therapeutic state. Ultimately, just as with the drug discovery process as a whole, successful biomarker discovery and development depends upon a clear understanding of the disease process. This article reviews the challenges of biomarker discovery with an emphasis on fluid biomarkers in neurodegeneration.
Literature
1.
Day M, Rutkowski JL, Feuerstein GZ. Translational medicine–a paradigm shift in modern drug discovery and development: the role of biomarkers. Adv Exp Med Biol. 2009;655:1–12.PubMedCrossRef
2.
Soares HD. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development. Curr Opin Investig Drugs. 2010;11:795–801.PubMed
3.
Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010;23:213–27.PubMedCrossRef
4.
Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson disease. J Geriatr Psychiatry Neurol. 2010;23:228–42.PubMedCrossRef
5.
Shi M, Caudle WM, Zhang J. Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol Dis. 2009;35:157–64.PubMedCrossRef
6.
Bahl JM, Jensen SS, Larsen MR, Heegaard NH. Characterization of the human cerebrospinal fluid phosphoproteome by titanium dioxide affinity chromatography and mass spectrometry. Anal Chem. 2008;80:6308–16.PubMedCrossRef
7.
Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129:526–9.PubMedCrossRef
8.
Calciano MA, Zhou W, Snyder PJ, Einstein R. Drug treatment of Alzheimer’s disease patients leads to expression changes in peripheral blood cells. Alzheimers Dement. 2010;6:386–93.PubMedCrossRef
9.
Nalls MA, Plagnol V, Hernandez DG, et al. Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet. 2011;377:641–9.PubMedCrossRef
10.
• Etheridge A, Lee I, Hood L, et al. Extracellular microRNA: a new source of biomarkers. Mutat Res 2011;717:85–90. This paper describes important new biomarker targets and methodologies, which will have a significant impact on future biomarker and drug discovery research.PubMedCrossRef
11.
Cogswell JP, Ward J, Taylor IA, et al. Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis. 2008;14:27–41.PubMed
12.
• Fehlbaum-Beurdeley P, Jarrige-Le Prado AC, Pallares D, et al. Toward an Alzheimer’s disease diagnosis via high-resolution blood gene expression. Alzheimers Dement 2010;6: 25–38. This paper describes important new biomarker targets and methodologies which will have a significant impact on future biomarker and drug discovery research. PubMedCrossRef
13.
Ikemura M, Saito Y, Sengoku R, et al. Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol. 2008;67:945–53.PubMedCrossRef
14.
Lebouvier T, Neunlist M, Bruley des Varannes S, et al. Colonic biopsies to assess the neuropathology of Parkinson’s disease and its relationship with symptoms. PLoS One. 2010;5:e12728.PubMedCrossRef
15.
Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathol. 2010;119:703–13.PubMedCrossRef
16.
17.
Waterton JC, Pylkkanen L. Qualification of imaging biomarkers for oncology drug development. Eur J Cancer. 2012;48:409–15.PubMedCrossRef
18.
Bansal S, DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS J. 2007;9:E109–14.PubMedCrossRef
19.
Kelley M, DeSilva B. Key elements of bioanalytical method validation for macromolecules. AAPS J. 2007;9:E156–63.PubMedCrossRef
20.
Viswanathan CT, Bansal S, Booth B, et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res. 2007;24:1962–73.PubMedCrossRef
21.
Nowatzke W, Woolf E. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. AAPS J. 2007;9:E117–22.PubMedCrossRef
22.
23.
Findlay JW, Smith WC, Lee JW, et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal. 2000;21:1249–73.PubMedCrossRef
24.
Valentin MA, Ma S, Zhao A, et al. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies. J Pharm Biomed Anal. 2011;55:869–77.PubMedCrossRef
25.
DeSilva B, Smith W, Weiner R, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res. 2003;20:1885–900.PubMedCrossRef
26.
Rhyne PW, Wong OT, Zhang YJ, Weiner RS. Electrochemiluminescence in bioanalysis. Bioanalysis. 2009;1:919–35.PubMedCrossRef
27.
Guglielmo-Viret V, Attree O, Blanco-Gros V, Thullier P. Comparison of electrochemiluminescence assay and ELISA for the detection of Clostridium botulinum type B neurotoxin. J Immunol Methods. 2005;301:164–72.PubMedCrossRef
28.
Mikulskis A, Yeung D, Subramanyam M, Amaravadi L. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development. J Immunol Methods. 2011;365:38–49.PubMedCrossRef
29.
Eglen RM, Reisine T, Roby P, et al. The use of AlphaScreen technology in HTS: current status. Curr Chem Genomics. 2008;1:2–10.PubMedCrossRef
30.
Gubala V, Le Guevel X, Nooney R, et al. A comparison of mono and multivalent linkers and their effect on the colloidal stability of nanoparticle and immunoassays performance. Talanta. 2010;81:1833–9.PubMedCrossRef
31.
Darmanis S, Nong RY, Hammond M, et al. Sensitive plasma protein analysis by microparticle-based proximity ligation assays. Mol Cell Proteomics. 2010;9:327–35.PubMedCrossRef
32.
Glickman JF, Wu X, Mercuri R, et al. A comparison of ALPHAScreen, TR-FRET, and TRF as assay methods for FXR nuclear receptors. J Biomol Screen. 2002;7:3–10.PubMedCrossRef
33.
Soderstrom CI, Spriggs FP, Song W, Burrell S. Comparison of four distinct detection platforms using multiple ligand binding assay formats. J Immunol Methods. 2011;371:106–13.PubMedCrossRef
34.
Morris JC, Selkoe DJ. Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview. Neurobiol Aging. 2011;32 Suppl 1:S1–3.PubMedCrossRef
35.
Gao CM, Yam AY, Wang X, et al. Abeta40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer’s disease. PLoS One. 2010;5:e15725.PubMedCrossRef
36.
Xia W, Yang T, Shankar G, et al. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol. 2009;66:190–9.PubMedCrossRef
37.
Jawhar S, Wirths O, Bayer TA. Pyroglutamate amyloid-beta (Abeta): a hatchet man in Alzheimer disease. J Biol Chem. 2011;286:38825–32.PubMedCrossRef
38.
Bjerke M, Portelius E, Minthon L, et al. Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010, 2010, Article ID 986310.
39.
Lewczuk P, Beck G, Esselmann H, et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem. 2006;52:332–4.PubMedCrossRef
40.
Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology. 2007;68:666–9.PubMedCrossRef
41.
Vogelgesang S, Jedlitschky G, Brenn A, Walker LC. The role of the ATP-binding cassette transporter P-glycoprotein in the transport of beta-amyloid across the blood–brain barrier. Curr Pharm Des. 2011;17:2778–86.PubMedCrossRef
42.
Silverberg GD, Messier AA, Miller MC, et al. Amyloid efflux transporter expression at the blood–brain barrier declines in normal aging. J Neuropathol Exp Neurol. 2010;69:1034–43.PubMedCrossRef
43.
Fujiyoshi M, Tachikawa M, Ohtsuki S, et al. Amyloid-beta peptide(1–40) elimination from cerebrospinal fluid involves low-density lipoprotein receptor-related protein 1 at the blood-cerebrospinal fluid barrier. J Neurochem. 2011;118:407–15.PubMedCrossRef
44.
Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010;330:1774.PubMedCrossRef
45.
Buchhave P, Minthon L, Zetterberg H, et al. Cerebrospinal Fluid Levels of beta-Amyloid 1–42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia. Arch Gen Psychiatry. 2012;69:98–106.PubMedCrossRef
46.
Bateman RJ, Munsell LY, Morris JC, et al. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12:856–61.PubMedCrossRef
47.
Bateman RJ, Siemers ER, Mawuenyega KG, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009;66:48–54.PubMedCrossRef
48.
Imbimbo BP, Peretto I. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer’s disease. Curr Opin Investig Drugs. 2009;10:721–30.PubMed
49.
Galimberti D, Scarpini E. Genetics and biology of Alzheimer’s disease and frontotemporal lobar degeneration. Int J Clin Exp Med. 2010;3:129–43.PubMedCrossRef
50.
Kim W, Lee S, Hall GF. Secretion of human tau fragments resembling CSF-tau in Alzheimer’s disease is modulated by the presence of the exon 2 insert. FEBS Lett. 2010;584:3085–8.PubMedCrossRef
51.
Yamada K, Cirrito JR, Stewart FR, et al. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci. 2011;31:13110–7.PubMedCrossRef
52.
Kovacech B, Novak M. Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer’s disease. Curr Alzheimer Res. 2010;7:708–16.PubMedCrossRef
53.
Portelius E, Hansson SF, Tran AJ, et al. Characterization of tau in cerebrospinal fluid using mass spectrometry. J Proteome Res. 2008;7:2114–20.PubMedCrossRef
54.
Fagan AM, Shaw LM, Xiong C, et al. Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of {beta}-Amyloid 1–42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pathology. Arch Neurol. 2011;68:1137–44.PubMedCrossRef
55.
Verwey NA, van der Flier WM, Blennow K, et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease. Ann Clin Biochem. 2009;46:235–40.PubMedCrossRef
56.
Mattsson N, Andreasson U, Persson S, et al. The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011;7:386–95. e386.PubMedCrossRef
57.
Vanderstichele H, Bibl M, Engelborghs S, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: A consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement. 2012;8:65–73.PubMedCrossRef
58.
Johansson P, Mattsson N, Hansson O, et al. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population. J Alzheimers Dis. 2011;24:537–46.PubMed
59.
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9.PubMedCrossRef
60.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.PubMedCrossRef
61.
Isaac M, Vamvakas S, Abadie E, et al. Qualification opinion of novel methodologies in the predementia stage of Alzheimer’s disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden–regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials. Eur Neuropsychopharmacol. 2011;21:781–8.PubMedCrossRef
62.
•• Holtzman DM, Goate A, Kelly J, Sperling R. Mapping the road forward in Alzheimer’s disease. Sci Transl Med 2011;3:114ps148. This is an important critical review of current biomarker approaches in neurodegeneration, and a studied proposal for future efforts.
63.
Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131–44.PubMedCrossRef
64.
Bjorkqvist M, Ohlsson M, Minthon L, Hansson O. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer’s disease. PLoS One. 2012;7:e29868.PubMedCrossRef
65.
Iwatsubo T. Aggregation of alpha-synuclein in the pathogenesis of Parkinson’s disease. J Neurol. 2003;250(3):III11–4.PubMed
66.
Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci. 2005;25:6016–24.PubMedCrossRef
67.
Liu J, Zhang JP, Shi M, et al. Rab11a and HSP90 regulate recycling of extracellular alpha-synuclein. J Neurosci. 2009;29:1480–5.PubMedCrossRef
68.
El-Agnaf OM, Salem SA, Paleologou KE, et al. Alpha-synuclein implicated in Parkinson’s disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003;17:1945–7.PubMed
69.
Mollenhauer B, El-Agnaf OM, Marcus K, et al. Quantification of alpha-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med. 2010;4:683–99.PubMedCrossRef
70.
Edwards TL, Scott WK, Almonte C, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet. 2010;74:97–109.PubMedCrossRef
71.
Beyer K. Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers. Acta Neuropathol. 2006;112:237–51.PubMedCrossRef
72.
Beyer K, Domingo-Sabat M, Lao JI, et al. Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics. 2008;9:15–23.PubMedCrossRef
73.
Beyer K, Lao JI, Carrato C, et al. Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies. Neuropathol Appl Neurobiol. 2004;30:601–7.PubMedCrossRef
74.
Chen L, Periquet M, Wang X, et al. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest. 2009;119:3257–65.PubMedCrossRef
75.
Hasegawa M, Fujiwara H, Nonaka T, et al. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem. 2002;277:49071–6.PubMedCrossRef
76.
Inglis KJ, Chereau D, Brigham EF, et al. Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem. 2009;284:2598–602.PubMedCrossRef
77.
Mbefo MK, Paleologou KE, Boucharaba A, et al. Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem. 2010;285:2807–22.PubMedCrossRef
78.
Paleologou KE, Oueslati A, Shakked G, et al. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci. 2010;30:3184–98.PubMedCrossRef
79.
Duda JE, Giasson BI, Chen Q, et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol. 2000;157:1439–45.PubMedCrossRef
80.
Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000;290:985–9.PubMedCrossRef
81.
Souza JM, Giasson BI, Chen Q, et al. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem. 2000;275:18344–9.PubMedCrossRef
82.
Hoyer W, Cherny D, Subramaniam V, Jovin TM. Impact of the acidic C-terminal region comprising amino acids 109–140 on alpha-synuclein aggregation in vitro. Biochemistry. 2004;43:16233–42.PubMedCrossRef
83.
Li W, West N, Colla E, et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson’s disease-linked mutations. Proc Natl Acad Sci U S A. 2005;102:2162–7.PubMedCrossRef
84.
Oueslati A, Fournier M, Lashuel HA. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson’s disease pathogenesis and therapies. Prog Brain Res. 2010;183:115–45.PubMedCrossRef
85.
Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem. 2010;56:177–85.PubMedCrossRef
86.
Nyhlen J, Constantinescu R, Zetterberg H. Problems associated with fluid biomarkers for Parkinson’s disease. Biomark Med. 2010;4:671–81.PubMedCrossRef
87.
Goodsaid F, Frueh F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J. 2007;9:E105–8.PubMedCrossRef
88.
Goodsaid FM, Mendrick DL. Translational medicine and the value of biomarker qualification. Sci Transl Med. 2010;2:47ps44.PubMedCrossRef
89.
Dieterle F, Sistare F, Goodsaid F, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol. 2010;28:455–62.PubMedCrossRef
90.
Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med. 2008;59:1–12.PubMedCrossRef
91.
Romero K, de Mars M, Frank D, et al. The coalition against major diseases: Developing tools for an integrated drug development process for Alzheimer’s and Parkinson’s diseases. Clin Pharmacol Ther. 2009;86:365–7.PubMedCrossRef
92.
Goodsaid F, Papaluca M. Evolution of biomarker qualification at the health authorities. Nat Biotechnol. 2010;28:441–3.PubMedCrossRef
93.
Broich K, Weiergraber M, Hampel H. Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements. Prog Neurobiol. 2011;95:498–500.PubMedCrossRef
94.
Regnier FE, Skates SJ, Mesri M, et al. Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration. Clin Chem. 2010;56:165–71.PubMedCrossRef
95.
Anderson L. Within sight of a rational pipeline for development of protein diagnostics. Clin Chem. 2012;58:28–30.PubMedCrossRef
96.
Scherf U, Becker R, Chan M, Hojvat S. Approval of novel biomarkers: FDA’s perspective and major requests. Scand J Clin Lab Invest Suppl. 2010;242:96–102.PubMedCrossRef
97.
98.
99.
Frasier M, Chowdhury S, Eberling J, Sherer T. Biomarkers in Parkinson’s disease: a funder’s perspective. Biomarkers Med. 2010;4:723–9.CrossRef
Metadata
Title
The Analytical Aspects and Regulatory Challenges of Biomarker Discovery: Examples from the Field of Neurodegeneration
Authors
Robert L. Martone
Richard Snyder
Arron S. L. Xu
Rachel Y. Reams
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Current Geriatrics Reports / Issue 2/2012
Electronic ISSN: 2196-7865
DOI
https://doi.org/10.1007/s13670-012-0015-4

Other articles of this Issue 2/2012

Current Geriatrics Reports 2/2012 Go to the issue

Biomarkers in the Classification of Biological Health and Disease Aging (Y Shen, Section Editor)

Spectrin Breakdown Products (SBDPs) as Potential Biomarkers for Neurodegenerative Diseases

Erratum

Erratum to: Animal Models of Alzheimer’s Disease: Utilization of Transgenic Alzheimer’s Disease Models in Studies of Amyloid Beta Clearance

Biomarkers in the Classification of Biological Health and Disease Aging (Y Shen, Section Editor)

Biomarkers of Cognitive Training Effects in Aging

Biomarkers in the Classification of Biological Health and Disease Aging (Y Shen, Section Editor)

Use of Telomere Length as a Biomarker for Aging and Age-Related Disease

Biomarkers in the Classification of Biological Health and Disease Aging (Y Shen, Section Editor)

Potential Blood Biomarkers in Age-related Cerebral Small Vessel Disease

Biomarkers in the Classification of Biological Health and Disease Aging (Y Shen, Section Editor)

Neuropsychological Parameters as Potential Biomarkers for Alzheimer’s Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits